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Our understanding of the mechanisms that regulate
hematopoietic stem/progenitor cells (HSPCs) has
been advanced by the ability to genetically manipu-
late mice; however, germline modification is time
consuming and expensive. Here, we describe fast,
efficient, and cost-effective methods to directly
modify the genomes of mouse and human HSPCs
using the CRISPR/Cas9 system. Using plasmid and
virus-free delivery of guide RNAs alone into Cas9-
expressing HSPCs or Cas9-guide RNA ribonucleo-
protein (RNP) complexes into wild-type cells, we
have achieved extremely efficient gene disruption
in primary HSPCs from mouse (>60%) and human
(75%). These techniques enabled rapid evaluation
of the functional effects of gene loss of Eed, Suz12,
and DNMT3A. We also achieved homology-directed
repair in primary human HSPCs (>20%). These
methods will significantly expand applications for
CRISPR/Cas9 technologies for studying normal and
malignant hematopoiesis.
INTRODUCTION
The ability to genetically manipulate the genomes of animal
models or isolated cells has driven hematopoietic stem cell
(HSC) research, revealing key mechanisms that control HSC
self-renewal and differentiation. Numerous genetically engi-
neered mouse models have contributed to our understanding
of the pathways that control HSCmaintenance and regenerationCell Rep
This is an open access article under the CC BY-Nin physiological settings (Rossi et al., 2012). Although this
approach produces invaluable insights and still remains a gold
standard in studying HSC biology, large time and cost commit-
ments are required to generate new mouse models, and the
approach is generally not amenable to high-throughput studies.
On the other hand, somatic engineering of hematopoietic stem/
progenitor cell (HSPC) genomes has been achieved, in large,
using retroviral vectors to either overexpress or knock down
the expression of genes of interest (Rivie`re et al., 2012). This
approach has been used to screen for both positive and negative
regulators of HSC function from up to 100 candidate genes (De-
neault et al., 2009; Hope et al., 2010). Although this approach al-
lows investigators to quickly assess the function of multiple
genes, retroviral transduction negatively impacts HSC function
during in vitro culture, and retroviral genome integration is a
serious concern when these engineered cells are used clinically
(Hacein-Bey-Abina et al., 2003). A new method to edit the ge-
nomes of HSPCs should not only accelerate gene discovery
research but also open up new clinical opportunities in using en-
gineered HSPCs for gene therapy.
Among the several engineered nucleases enabling site-spe-
cific genome editing, the CRISPR-Cas9 system (Jinek et al.,
2012) stands out since it does not require cumbersome engi-
neering of nucleases for each target and only requires a 20-nt
RNA sequence contained within a chimeric single-guide RNA
(sgRNA) to drive the endonuclease Cas9 to its target sequence.
Thus, CRISPR/Cas9 provides a versatile, modular, and cost-
effective means to edit the genomes of multiple model systems
(Hsu et al., 2014; Sternberg and Doudna, 2015). Several delivery
methods have been used to perform CRISPR/Cas9-mediated
gene editing of HSPCs, including lentiviral transduction (Heckl
et al., 2014), plasmid DNA transfection (Mandal et al., 2014), or
chemically modified RNA (Hendel et al., 2015), achieving up toorts 17, 1453–1461, October 25, 2016 ª 2016 The Author(s). 1453
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
48% gene disruption in human HSPCs. While these studies have
shown the enormous potential of HSPCgene editing byCRISPR/
Cas9, a method that is highly efficient and simple, without the
need for any cloning and nucleotide modifications, and that
addresses clinical concerns of retroviral genome insertion is still
lacking. We sought to develop simple strategies to perform
CRISPR/Cas9-mediated gene editing in HSPCs with minimal
manipulations and while avoiding viral integration into the
HSPC genome. Here we describe fast, efficient, and cost-effec-
tive methods of CRISPR/Cas9-mediated gene editing in primary
murine and human HSPCs, and we demonstrate that this
method can be used to directly examine gene function.
RESULTS
Efficient Gene Disruption in Mouse HSPCs
We reasoned that transfecting HSPCs isolated from Cas9-ex-
pressing mice (Platt et al., 2014) with sgRNA would be an effi-
cient method to edit the genome of HSPCs, since only the small
RNA molecules would need to be introduced. To test this idea,
we designed small guide RNAs to target the GFP gene (GFP-
sg1) co-expressed in the Cas9-expressing mice. When we elec-
troporated c-kit+ HSPCs with in vitro-transcribed GFP-sg1, we
observed highly efficient loss of GFP expression by flow cytom-
etry, compared to cells electroporated with sgRNA against
Rosa26 (R26-sg) (Figure 1A). Although electroporation reduced
the survival of HSPCs 20% immediately after electroporation,
cells maintained at least 80% viability throughout the experiment
for up to 96 hr post-electroporation (Figure 1B). In this condition
maintaining high viability, we found that 67% ± 4% of HSPCs
lost GFP expression upon electroporation of GFP-sg1 (Figures
S1A and S1B), demonstrating efficient gene editing with high
cell viability. The frequency of GFP ablation exhibited a sgRNA
dose-dependent increase, plateauing at 1 mg GFP-sg1 for 105
HSPCs per transfection (Figure 1C).
Because retroviral transduction is enhanced by culturing with
cytokines to stimulate the cell cycle of quiescent HSPCs, we also
tested whether brief in vitro exposure to cytokines in culture
before sgRNA electroporation increased GFP gene editing. We
electroporated Cas9-expressing HSPCs after varying the dura-
tion of culture. We found that a brief culture (1–3 hr) increased
the frequency of GFP-negative cells from around 60% in fresh
progenitors to amaximumof 85% ± 1%after 3 hr, without further
increase after 12 hr (Figure 1D). In the context of this gene-edit-
ing strategy, incorporation of an optimized scaffold sequence
previously shown to improve Cas9-mediated imaging (Chen
et al., 2013) did not significantly increase the frequencies of
gene disruption further (Figure S1C).
Because the c-kit+ population contains various progenitors
besides HSCs, we tested whether HSCs themselves undergo
successful gene disruption upon transfection of sgRNAs. After
electroporation of Cas9-expressing c-kit+ cells with GFP-sg1,
we sorted CD150+CD48lineageSca-1+ cells (c-kit expression
was attenuated within 1 hr of pre-culture before electroporation,
Figure S1D) into semi-solid media, and we monitored colonies
arising from these single HSCs for GFP ablation. Flow cytometry
of individual colonies revealed that most HSC-derived colonies
(40 of 48: 83%) lost GFP expression (representative three col-1454 Cell Reports 17, 1453–1461, October 25, 2016onies shown in Figure 1E), whereas electroporation with or
without sgRNA did not affect the clonality of HSCs compared
to cultured, un-electroporated cells (Figure S1E). Thus, our
method efficiently ablates genes in HSCs with minimum impact
on HSC survival.
With the optimized sgRNA delivery method in hand, we next
considered whether Cas9 protein pre-complexed with sgRNA
to generate a ribonucleoprotein (RNP) particle (Kim et al.,
2014; Lin et al., 2014; Schumann et al., 2015) also could be
used to edit genes in murine HSPCs. Different amounts of
GFP-sg1 were mixed with Cas9 protein, and the RNP complex
was electroporated into HSPCs isolated from a mouse strain
that ubiquitously expresses GFP (Schaefer et al., 2001). As
shown in Figures 1F and 1G, 70% of HSPCs lost GFP expres-
sion upon co-delivery of Cas9 protein and GFP-sg1. Two other
sgRNAs against GFP also attenuated GFP expression in signifi-
cant fractions of HSPCs (Figure S1G). Under this condition,
HSPCs electroporated with Cas9 RNP maintained viability
of >80% for up to 96 hr after electroporation (Figure S1F). Since
loss of GFP expression is an indirect measure of genome editing,
we directly examined insertion or deletion (indel) frequencies
at the genomic level. First, we performed T7 endonuclease I
(T7E1) assays and found that a significant fraction of HSPCs
accrued indels (Figure 1H). We note that the T7E1 assay often
underestimates the rate of indel formation, potentially due to
self-hybridization of the alleles that carry the indel, incomplete
duplex melting, and inefficient cleavage of single nucleotide in-
dels (Schumann et al., 2015). To accurately determine the nature
of the indels, we next performed high-throughput sequencing,
which revealed that 60% of HSPCs accrued small indels
(Figure S1H; Table S2). These genomic analyses corroborated
the flow cytometry data demonstrating that GFP alleles were
mutated by the Cas9 RNP approach. Thus, this strategy allows
us to study gene function directly in HSPCs in any genetic
background.
Functional Assessment of Gene Disruption in Mouse
HSPCs
We then tested whether targeted gene editing in HSPCs by
CRISPR/Cas9 could be used to alter HSPC function. We chose
to disrupt two polycomb-repressive complex 2 (PRC2) compo-
nents Eed and Suz12, which are both found mutated in human
leukemias (Shih et al., 2012). It has been shown that monoalleleic
loss, but not biallelic loss, of Eed or Suz12 confers proliferative
advantages to HSPCs (Lee et al., 2015; Xie et al., 2014). We
transfectedwild-type HSPCswith Cas9-RNP complexes against
Rosa26, Eed, or Suz12; plated them on semi-solid media;
and serially replated the cells. Whereas most Rosa26-targeted
HSPCs lost proliferative capacity upon the fourth replating,
Eed- and Suz12-targeted HSPCs exhibited extensive prolifera-
tive capacity at the fourth passage (Figure 2A). T7E1 assays per-
formed on HSPC cultures shortly (48 hr) after electroporation
revealed that a substantial fraction of cells accrued indels in
Eed and Suz12 (Figure 2B). Sanger sequencing and tracking
of indels by decomposition (TIDE) analysis (Brinkman et al.,
2014) revealed that 50% of the sequence reads accrued small
indels between 4-bp deletion and 2-bp insertion (Figures S2A
and S2B).
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Figure 1. Gene Editing in Murine HSPCs
(A) A representative flow cytometry histogram showing efficient ablation of GFP by electroporating GFP-sg1 into Cas9-expressing HSPCs. Black histogram
represents GFP HSPCs, and green and red histograms represent Rosa26 (R26)- and GFP-disrupted HSPCs, respectively (n = 3).
(B) Survival of HSPCs was determined by trypan blue staining of cells cultured without electroporation, cells mock electroporated without sgRNA, and cells
electroporated with R26 or GFP sgRNA. 1 mg of sgRNA was used to electroporate 105 cells (n = 3).
(C) Deletion efficiencies of GFP exhibiting sgRNA dose-dependent response. A plateau in gene-editing efficiency was reached by 1 mg sgRNA/105 cells (n = 3).
(D) A brief culture of murine HSPCs for 1–3 hr increased gene-editing frequency, while overnight (O/N) culture did not further increase gene editing (n = 3).
(E) After electroporating c-kit+ HSPCs with GFP-sg1, HSCs were sorted clonally into methylcellulose media. Most (40 of 48) HSC colonies exhibited loss of GFP
expression, as shown by the representative flow cytometry histograms for three HSC-derived colonies from one donor mouse (n = 3 independent experiments).
(F) A representative histogram demonstrates efficient ablation of GFP expression by electroporating Cas9/GFP-sg1 RNP into GFP-expressing HSPCs (n = 3).
(G) Quantification of results in (F). Even as little as 200 ng GFP-sg1 efficiently ablated GFP upon delivery with Cas9 protein (1 mg).
(H) T7E1 assays performed with GFP amplicon derived from R26- or GFP-disrupted HSPCs. PCR amplicons were either treated (+) or untreated () with T7E1.
Arrowheads indicate the bands with expected size assuming small indels, based on the Cas9 cleavage site. 1 mg of sgRNA was used to electroporate 105 Cas9-
expressing cells unless otherwise noted. All data represent mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.001 by Student’s t test). See also Figure S1.We also cloned individual colonies at later passages and
examined the editing status. T7E1 assay revealed that Eed-
and Suz12-edited colonies acquired indels, and sequencing
verified that they all acquired monoallelic loss of Eed or
Suz12 (Figures 2C–2F), consistent with the haploinsufficientfunction of Eed and Suz12 (Lee et al., 2015; Xie et al.,
2014). These results establish that Cas9 RNPs can be used
to perform gene editing in primary murine HSPCs regardless
of genetic background, resulting in clear loss-of-function
phenotypes.Cell Reports 17, 1453–1461, October 25, 2016 1455
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Figure 2. Editing Endogenous Genes in
Murine HSPCs
(A) Gene editing of Eed or Suz12 using Cas9-sgRNA
RNP increased the ability of murine HSPCs to seri-
ally replate in culture; 1 mg Cas9 protein and 1 mg
sgRNA were used (n = 4).
(B) T7E1 assays performed with Eed (top) or Suz12
(bottom) amplicon derived from Rosa26- (R26),
Eed-, or Suz12-disrupted HSPCs 48 hr after elec-
troporation. The numbers below the gel image
represent the cleavage efficiency determined by
densitometric analysis (n = 3).
(C and D) T7E1 assays performed with Eed (C)
or Suz12 (D) amplicons derived from Rosa26- (R26),
Eed-, or Suz12-disrupted colonies, with (+) or
without () the nuclease (n = 4). Arrowheads indi-
cate the bands with expected size based on the
Cas9 cleavage site, whereas asterisks indicate non-
specific bands.
(E and F) Sequencing results of representative four
clones each (of 12) after electroporating with Eed (E)
or Suz12 (F) sgRNA. All colonies analyzed (Eed, 12/
12; Suz12, 12/12) acquired indels. Red line repre-
sents the position of the protospacer adjacent motif
(PAM) sequence. All data represent mean ± SD
(***p < 0.001 by Student’s t test). See also Figure S2.Efficient Gene Disruption in Human HSPCs
Encouraged by the results obtained in mice, we assessed the
feasibility and efficiency of our protocol in human hematopoietic
cells. We first sought to target human CD45 (hCD45) in HL-60
cells, a human acute myeloid leukemia (AML) cell line. We elec-
troporated HL-60 cells with Cas9/hCD45-sg RNPs testing three
different CD45 guides. Strikingly, all three guides displayed very
high efficiencies of disrupting CD45 expression (sg1, 98%; sg2,
91%; and sg3, 74%), as assessed by flow cytometry (Fig-
ure S3A). Two additional AML cell lines, OCI-AML2 and Kasumi,
exhibited similar editing efficiencies (Figure 3A).
We also tested whether our protocol was capable of editing
peripheral blood mononuclear cell (PBMC)-derived primary T
lymphocytes. While resting T cells were resistant to CD45 edit-
ing (data not shown), activated T cells targeted with hCD45-sg1
exhibited efficient (86% ± 2%; n = 3) loss of CD45 (Figure 3A),
with some residual CD45bright and CD45mid cells (Figure S3B).
We performed high-throughput sequencing of unfractionated
T cells as well as cells sorted based on CD45 expression
(CD45bright, CD45mid, CD45dim, and CD45neg cells), and we
discovered that, while the unfractionated cells had an indel
frequency of 83%, more than 95% of alleles in CD45neg and
CD45dim cells and 40% of alleles in CD45mid cells had acquired
indels (Figure S3B). Interestingly, CD45dim cells harbored 51%
in-frame and 49% out-of-frame indels (Figure S3C), which
may explain the residual CD45 expression (Figure S3C). Impor-
tantly, low indel frequencies (0.2%, 1.7%, and 0.4%; read
depth: 924, 301, and 527) were observed at the top three
predicted off-target (OT) sites (Figure 4B; Supplemental Exper-
imental Procedures).
We then tested whether primary human CD34+ HSPCs could
be gene edited. To search for the optimal conditions, we first
electroporated primary CD34+ cells derived from umbilical1456 Cell Reports 17, 1453–1461, October 25, 2016cord blood with Cas9/hCD45-sg1 RNP using nine different elec-
troporation parameters, and we performed flow cytometry 96 hr
later to measure CD45 expression levels together with cell
viability (Figure S3D). The optimized electroporation parameter
(condition 9) was used for all further experiments. Since short-
term ex vivo expansion is routinely exploited to increase trans-
fection and transduction efficiency, we explored the impact of
short cytokine exposure on transfection and gene disruption
efficiency. We electroporated CD34+ cells from single donors
(n = 5) with mRNA encoding for GFP-fused Nucleophosmin 1
(GFP-NPM1) immediately after isolation, or after 24 or 48 hr of
cytokine exposure, and we analyzed GFP expression 24 hr later.
While fresh cells showed only 28% ± 13% GFP positivity, cells
cultured for either 24 or 48 hr displayed transfection efficiencies
higher than 75% (24 hr, 81% ± 12%; 48 hr, 78% ± 10%)
(Figure S3E).
To assess whether CRISPR-mediated gene disruption effi-
ciency was influenced by exposure to cytokines, we performed
a similar experiment electroporating CD34+ from single donors
(n = 8) with Cas9/hCD45-sg1 RNP again at 0, 24, and 48 hr of cul-
ture, and we analyzed CD45 expression 4 days later. As ex-
pected, freshly isolated CD34+ cells not exposed to cytokines
exhibited limited loss of CD45 cell surface expression (8% ±
4%). However, gene disruption efficiency was significantly
higher in cells cultured for 48 hr compared to 24 hr (73% ±
16% versus 41% ± 12%, p = 0.003) (Figure 3B), implying that
the efficiency of gene disruption is dependent upon more
than transfection efficiency. Importantly, CD34 expression re-
mained unchanged even following efficient CD45 knockout
(Figure 3C).
We also determined the impact of CRISPR-Cas9 delivery on
human HSPC viability. CD34+ cells from single donors were
electroporated with Cas9 only or Cas9/hCD45-sg1 RNP or left
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Figure 3. Efficient CD45 Knockout in Human Hematopoietic Cells
(A) Flow cytometry analysis of hCD45 expression in three AML cell lines and activated primary T cells 96 hr following electroporation with Cas9 only (blue) or Cas9/
hCD45-sg1 RNP (red) is shown.
(B) Effects of pre-culture before electroporation on gene disruption efficiency. hCD45 loss was examined in CD34+ cells cultured for 0, 24, and 48 hr in the
presence of cytokines before electroporation with Cas9/hCD45-sg1 RNP. hCD45 expression was evaluated 4 days after electroporation. Each experiment (n = 8)
was performed on CD34+ cells isolated from single donors.
(C) Flow cytometry analysis of CD45 and CD34 expression in CD34+ cells 96 hr following electroporation with Cas9 only (left) or Cas9/hCD45-sg1 RNP (right) is
shown.
(D and E) Cell viability examined by trypan blue staining (D, n = 8) or flow cytometry (E, n = 6) of CD34+ cells electroporated either with Cas9 only (black) or with
Cas9/hCD45-sg1 RNP (gray) relative to non-electroporated cells at the indicated time points. The cell counts (D) or viability (E) of Cas9 only- and Cas9/hCD45-
sg1-transfected cells was compared to the viable cell counts of non-electroporated cells.
All data represent mean ± SD; *p < 0.05, **p < 0.01, and ***p < 0.001 by non-parametric tests.untreated in culture, and viable cell counts were recorded by try-
pan blue staining at 24, 60, and 96 hr after electroporation. Non-
electroporated cells expanded in vitro, reaching 2.1 3 105 cells,
5 3 105 cells, and 1.1 3 106 cells at 24, 60, and 96 hr of culture,
respectively, starting with 105 cells. Electroporated cells ex-
hibited significant but acceptable cell loss in Cas9/hCD45-sg1 RNP-treated cells compared to non-electroporated cells
(24 hr, 69% ± 31%; 60 hr, 40% ± 13%; 96 hr, 34% ± 17%;
n = 8) (Figure 3D). Cell viability assessed by flow cytometry at
48 and 96 hr corroborated these results (48 hr, 48% ± 18%;
96 hr, 45% ± 11%; n = 6) (Figure 3E). These results are consis-
tent with those reported by others using electroporation ofCell Reports 17, 1453–1461, October 25, 2016 1457
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Figure 4. CRISPR-Cas9-Mediated Gene Disruption and HDR in Human HSPCs
(A) Indel frequencies at targeted loci. When multiple sgRNAs were used in the same experiment, sg1 indicates alleles with disruption of sg1 only, sg2 indicates
alleles with disruption of sg2 only, and a triangle indicates alleles with a deletion between sg1 and sg2. Raw allele counts for each indel/deletion are found in
Table S2.
(B) Indel frequencies at three predicted hCD45-sg1 OT sites. OT sites (OT1–3) were predicted using CRISPRscan (Moreno-Mateos et al., 2015).
(C) Plots showing percentages of human cells (left) in the bonemarrow and the spleen of 16 NSG recipient mice (eight Cas9 only and eight Cas9/hCD45-sg1 RNP)
and the fraction of engrafted human cells that have lost hCD45 (right) in Cas9 only (black) and Cas9/hCD45-sg1 RNP (red). Human CD34+ cells from individual
cord blood donors were electroporated with Cas9 only and Cas9/hCD45-sg1 RNP, and they were transplanted into sublethally irradiated NSGmice. Engraftment
was analyzed 8 weeks post-transplant.
(legend continued on next page)
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site-directed nucleases (De Ravin et al., 2016; Genovese et al.,
2014).
CD45 knockout efficiency measured by flow cytometry
(73% ± 16%) was confirmed by high-throughput sequencing
of the hCD45 locus (75% ± 10%) (Figure 4A; Table S2). As
in T cells, CD34+ cells electroporated with Cas9/hCD45-sg1
(n = 3) displayed minimal OT cleavage (1.0%, 7.0%, and
0.1%; average read depth: 5,319, 5,164, and 5,089 at OT1,
OT2, and OT3, respectively) (Figure 4B). To verify that the edi-
ted CD34+ HSPCs maintained engraftment and multilineage
differentiation capacity, we transplanted Cas9-only (n = 8)
and Cas9/hCD45-sg1 RNP-edited cells (n = 8) into sub-lethally
irradiated NOD scid gamma (NSG) mice. To avoid possible
donor-dependent bias, each experimental pair (i.e., one
Cas9-only replicate and one Cas9/hCD45-sg1 RNP-treated
replicate) was performed on cells derived from a single cord
blood. Bone marrow of 16/16 recipients and spleens of 13/16
recipients were successfully engrafted with human cells (Fig-
ure 4C). Importantly, we observed significant levels of engraft-
ment by hCD45neg cells in the bone marrow of 7/8 mice and in
the spleen of 5/8 mice transplanted with Cas9/hCD45-sg1
RNP-edited cells (Figures 4C, 4D, and S4A). Sequencing of
the amplified human CD45 locus from bone marrow cells
confirmed the presence of indels with frequencies consistent
with flow cytometry data (Figure S4B). As expected for this
time point (Goyama et al., 2015; McDermott et al., 2010), en-
grafted human HSPCs gave rise mainly to B and myeloid cells
in the bone marrow in both Cas9 only- and Cas9/hCD45-sg1
RNP-engrafted mice, with no differences between these two
groups (Figure S4C). The Cas9/hCD45-sg1 RNP-edited sam-
ples displayed no significant difference in CD45 gene disruption
between B and myeloid cells (Figure S4D).
We also analyzed human CD34+ HSPCs in one bone marrow
sample in which 37%of engrafted human cells were CD45 nega-
tive. CD45 loss was evident in 40% of CD34+ cells (Figure S4E)
and 36% of the CD34+CD38 population, which contained
the most immature progenitor cells. These results establish
that our method allows for efficient gene disruption of human
CD34+ HSPCs while retaining multilineage reconstitution capac-
ity and the ability of these cells to engraft and expand in recipient
mice. Given the known limitations of NSGmice to support robust
generation of cells from all human hematopoietic lineages, such
as T cells and erythroid cells, further assessment in additional
models and longer time points will reveal whether the most
long-term HSCs are successfully modified and viable after these
treatments.(D) Flow cytometry analysis of two engrafted NSGmice. Top panels show the engr
presence of hCD45 knockout cells (highlighted in red) both in the bone marrow a
(E) Western blot analysis of DNMT3A expression in CD34+ cord blood cells 96 h
exon 7/8-sg (four sgRNAs) RNP, or Cas9/DNMT3A exon 7-sg (two sgRNAs) RNP
(F) Schematic representation of the CRISPR-mediated knockin (top). Three sing
restriction site (italics), were introduced into hCD45 exon 25. The most commonl
precise (HDR; all three single-nucleotide changes) and imprecise (HDR*; two of
sequencing, and their allele frequencies are displayed. The numbers in red repre
(G) A gel image of BsiWI-digested PCR amplicon prepared from CD34+ cord blo
stranded DNA oligonucleotides (ssODN) containing BsiWI sites. Both symmetric
amplicon with HDR editing into 172-bp and 110-bp fragments. The numbers b
determined by high-throughput sequencing.Multiple Guide Approach Allows for Rapid Deletion of
Genes of Interest
To ensure functional ablation of a target gene and to facilitate
rapid assessment of gene editing by PCR, larger deletions are
often desirable. Thus, we synthesized guide RNA pairs targeting
exons 7–14 of DNMT3A. We tested combinations of up to four
guides per electroporation in HL-60 cells, assessing the fre-
quency and spectra of deletions after 12 hr and the level of
DNMT3A protein after 96 hr. All tested combinations of guides
demonstrated efficient deletions and significantly diminished
DNMT3A protein (Figure S4G).
We then targeted DNMT3A in primary CD34+ cord blood cells.
Guides targeting exons 7 and 8 were tested and the expected
deletions were observed by PCR (Figure S4F). Importantly, the
DNMT3A protein was nearly absent 96 hr after disruption of
exon 7 or exons 7+8 (Figure 4E). To verify this result, DNMT3A
exon 7 was targeted in CD34+ cells enriched from an additional
five cord blood samples, and high-throughput sequencing
confirmed a gene disruption frequency of 69% ± 4% (Figure 4A;
Table S2), suggesting that most cells likely experience loss of at
least one allele, whereas many cells lose both alleles. To further
validate the flexibility and efficiency of our approach, we targeted
exon 10 of DNMT3A (n = 10) and exon 3 of NR3C1 (n = 5) in
CD34+ cells, and high-throughput sequencing showed allelic
disruption frequencies of 86% ± 14% and 75% ± 6%, respec-
tively (Figures 4A and S4H; Table S2).
Efficient HDR-Mediated Gene Editing in Human HSPCs
Finally, we considered whether these editing strategies could be
used to introduce specific point mutations into primary human
HSPCs using Cas9-mediated homology-directed repair (HDR).
HDR would enable specific lesions to be introduced in HSPCs,
potentially correcting deleterious mutations or mimicking
cancer-associated mutations. Single-stranded oligonucleotide
HDR templates (ssODNs) were designed with symmetric or
asymmetric homology arms (Richardson et al., 2016) to intro-
duce three base pair changes, two of which resulted in the gen-
eration of a BsiWI site near the hCD45-sg1 spacer sequence
(Figure 4F). After 48 hr of culture with cytokines, CD34+ HSPCs
were electroporated with the Cas9/hCD45-sg1 RNP along with
either 10 or 30 pmol ssODNs. The addition of 10 or 30 pmol
ssODNs did not significantly affect the viability (Figures S3F
and S3G), although a trend toward lower viability after electropo-
ration with a higher dose of ssODN was observed. Following
BsiWI digestion of genomic DNA 24 hr after transfection, all sam-
ples with a donor template displayed a digested band, indicatingaftment of normal human cells (CD45posHLA-ABCpos). Bottom panels show the
nd the spleen.
r after electroporation with Cas9 only, Cas9/hCD45-sg1 RNP, Cas9/DNMT3A
is shown.
le-nucleotide changes, two of which (red) resulted in the formation of a BsiWI
y observed alleles from a representative sample (bottom), which included both
three nucleotide changes) knockin events, were assessed by high-throughput
sent frequencies of reads containing the BsiWI restriction site.
od cells targeted with Cas9/hCD45-sg1 (1 mg each) RNP and different single-
(S) and asymmetric (A) homology arms were tested. BsiWI digests the 282-bp
elow the gel represent efficiency of restriction site knockin (HDR+HDR*) as
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successful HDR (Figure 4G). High-throughput sequencing per-
formed on these samples revealed efficient precise knockin
(22%; range: 19%–25%) of the mutant allele (Figure 4F; Table
S2). Additionally, many reads (1%–2%) displayed imprecise or
partial knockin of the mutant allele (one of three or two of three
bases) (Figure 4F; Table S2). Samples electroporated with only
the donor template displayed no detectable mutant allele by
high-throughput sequencing (data not shown). Thus, our method
allows homology-directed gene editing at a substantial fre-
quency in human HSPCs. Additional testing in multiple mouse
and other animal models will be required to establish whether
the most long-term HSCs are successfully edited.
DISCUSSION
The strategies we describe herein enable efficient gene editing,
particularly loss-of-function studies, in both murine and human
HSPCs directly. With the RNP-based methods, it is possible
to generate gene-edited HSPCs within a week starting with
conception of the study, including downtime for oligonucleotide
synthesis. This is substantially shorter than editing HSPCs using
lentiviral transduction, which requires cloning sgRNAs into lenti-
viral vectors, generation and quality control of lentiviral particles,
and results in variable HSPC transduction efficiencies and risks
of lentiviral integration in undesirable sites. Furthermore, electro-
poration of RNPs is a transient hit-and-run approach that obvi-
ates the need for a special mouse strain expressing Cas9, and
it reduces concerns of constitutive Cas9 expression and OT
cleavage. The costs of generating gene-edited HSPCs with
these methods are substantially lower than those with lentiviral
methods. Although commercially available Cas9 protein makes
gene ablation with RNPs feasible, we also envision this strategy
could be used for other Cas9 derivatives where transient effects
may be desirable, such as CRISPR interference (Konermann
et al., 2015; Qi et al., 2013).
One limitation of our protocol is that it lacks the ability to mark
the cells that were successfully electroporated, unlike lentiviral
transduction methods in which transduced cells can be marked
by fluorescent proteins or by antibiotic resistance. However, with
a gene-editing efficiency approaching 90%aswe show for some
targets, our method makes it possible to examine the molecular
or phenotypic changes without selection for transfected cells.
We have shown that deletion of DNMT3A from primary human
CD34+ cells leads to a precipitous reduction in DNMT3A protein
levels in the population within 96 hr after electroporation.
We have observed that gene-editing efficiency is slightly more
efficient in human than murine HSPCs. It is possible that this dif-
ference reflects developmental states, since the human cells are
derived from cord blood rather than bone marrow. Additional
optimization using murine HSPCs from the fetal liver or after
mobilization may further increase the gene-editing efficiency.
Perhaps themost significant finding we observed was efficient
HDR in human HSPCs. The ability to introduce specific muta-
tions in HSPCs will enable the expanded study of cancer-driver
mutations in AML and other hematologic diseases. More impor-
tantly, the repair of inherited mutations in both common and rare
blood disorders using CRISPR may now be feasible without
integration of viral vectors or delivery of plasmid DNA, represent-1460 Cell Reports 17, 1453–1461, October 25, 2016ing a major stepping-stone toward therapeutic gene editing. We
have not yet achieved detectable HDR frequencies in mouse
HSPCs, and it is possible that a longer culture time prior to elec-
troporation is necessary to activate this repair process in murine
cells.
These remarkable knockout and HDR efficiencies in human
HSPCs may suggest the possibility of broad and immediate util-
ity. However, most ex vivo manipulations ultimately have been
shown to impact function of the most long-term HSCs (Geno-
vese et al., 2014; Hoban et al., 2015), and all of the available as-
says have limitations in their ability to assess bona fide HSC
function. Therefore, caution in application of these strategies is
still warranted.
In conclusion, we describe a fast, efficient, and cost-effective
method to edit the genomes of both murine and human HSPCs
based on the CRISPR/Cas9 system. The ability to quickly and
efficiently edit primary HSPCs makes it possible to test the func-
tion of genetic variants identified in association with hematologic
diseases, such as leukemia or bone marrow failure. Moreover,
the high efficiency offers the possibility to perform large-scale
combinatorial gene editing in HSPCs to model complex muta-
tional landscapes.
EXPERIMENTAL PROCEDURES
Production of sgRNA and Electroporation
Protospacer sequences for each target gene were identified using the
CRISPRscan algorithm (http://www.crisprscan.org) (Moreno-Mateos et al.,
2015). DNA templates for sgRNAs were made using the protocol described
by Li et al. (2013) using primers listed in Table S1. The sgRNA (1 mg) was
electroporated into 1 3 105 Cas9-expressing c-kit+ murine HSPCs after 1–
3 hr of culture. The optimized electroporation condition for murine HSPCs
was 1,700 V, 20 ms, and one pulse, using a Neon transfection system (Thermo
Fisher Scientific). To electroporate Cas9-sgRNA RNPs, 200 ng to 1 mg sgRNA
was incubated with 1 mg Cas9 protein (PNABio) for 10–15min at room temper-
ature and electroporated as above. Human CD34+ cells were isolated by
AutoMACS (Miltenyi Biotec) using CD34 microbeads, and they were electro-
porated as described for murine cells except the optimized electroporation
condition was 1,600 V, 10 ms, and three pulses. See the Supplemental
Experimental Procedures for details.
Statistical Analysis
For comparisons involving two groups, unpaired Student’s t tests (two-tailed)
or non-parametric tests were used. See the figure legends for details.
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